GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-1)’. This study aims to evaluate the efficacy and safety of depemokimab as an add-on treatment for adults with moderate to severe COPD who have type 2 inflammation, potentially offering a new therapeutic option for this challenging condition.
The study is testing depemokimab, an experimental drug, against a placebo. Both are administered alongside standard care. Depemokimab is designed to help manage COPD symptoms by targeting type 2 inflammation.
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study. It involves multiple centers and employs quadruple masking, meaning neither participants, caregivers, investigators, nor outcome assessors know who receives the actual drug or placebo. The primary purpose is treatment-focused.
The study began on June 20, 2025, with the latest update submitted on June 30, 2025. These dates mark the study’s initiation and the most recent information available, crucial for tracking progress and updates.
This study could significantly impact GSK’s stock performance and investor sentiment, as successful results may enhance GSK’s portfolio in the respiratory treatment market. Investors should watch for developments, especially considering the competitive landscape in COPD treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.